With the COVID-19 pandemic now ongoing for close to a year, people all over the world are
still waiting for a vaccine to become available. The initial focus of accelerated global …

Infectious diseases, along with cancers, are among the main causes of death among
humans worldwide. The production of therapeutic proteins for treating diseases at large …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a respiratory
disease called coronavirus disease 2019 (COVID-19), the spread of which has led to a …

The recently emerged Omicron (B. 1.1. 529) variant has rapidly surpassed Delta to become
the predominant circulating SARS-CoV-2 variant, given the higher transmissibility rate and …

In December 1983, a seminal paper appeared on the overexpression of human IFN-β in
insect cells with a genetically engineered baculovirus. The finding that baculoviruses …

Recombinant proteins are produced for various applications in laboratory and industrial
settings. Among them, therapeutic applications have evolved into a mature field in recent …

Almost all therapeutic proteins are glycosylated, with the carbohydrate component playing a
long-established, substantial role in the safety and pharmacokinetic properties of this …

The Baculovirus Expression Vector System (BEVS), a mature foreign protein expression
platform, has been available for decades, and has been effectively used in vaccine …

Eukaryotic membrane proteins, many of which are key players in various biological
processes, constitute more than half of the drug targets and represent important candidates …

Several epidemic and pandemic diseases have emerged over the last 20 years with
increasing reach and severity. The current COVID-19 pandemic has affected most of the …